# A Clinical Trial of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)

> **NCT07648641** · — · NOT_YET_RECRUITING · sponsor: **CanSino Biologics Inc.** · enrollment: 100 (estimated)

## Conditions studied

- Pneumococcal Infections
- Streptococcal Infections
- Bacterial Infections

## Interventions

- **OTHER:** Previously vaccinated with PCV13 (CanSino)
- **OTHER:** Previously vaccinated with PCV13 (Pfizer)

## Key facts

- **NCT ID:** NCT07648641
- **Lead sponsor:** CanSino Biologics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2027-12-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07648641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07648641, "A Clinical Trial of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07648641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*